Overview
- 12 inspections across 12 sites are on record.
- 195 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-05-31.
At a glance
Inspections
12
Sites
12
Observations
195
Career since
Mar 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| IDT Australia Limited | 31 May 2019 | Human Drugs | On file |
| Tanvex BioPharma USA, Inc | 2 May 2019 | Human Drugs | On file |
| Pyramid Laboratories, Inc. | 11 Apr 2019 | Human Drugs | View 483 → |
| Teva Parenteral Medicines Inc | 18 Jan 2019 | Human Drugs | View 483 → |
| University of Southern CA, DBA USC Molecular Imaging Center | 9 Aug 2018 | Human Drugs | On file |
Sites inspected
IDT Australia LimitedBoronia, Australia1 insp.
Tanvex BioPharma USA, IncSan Diego, United States1 insp.
Pyramid Laboratories, Inc.Costa Mesa, United States1 insp.
Teva Parenteral Medicines IncIrvine, United States1 insp.
University of Southern CA, DBA USC Molecular Imaging CenterLos Angeles, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Walden H Lee6 shared
Amir Alavi3 shared
Carrie A Hughes3 shared
Linda Thai2 shared
Evelyn Wong2 shared
Frances Namuswe1 shared
Lindsey J Brown1 shared
Jolanna A Norton1 shared
Thuy T Nguyen1 shared
Christopher R Czajka1 shared
Full investigator report
Get the verbatim findings behind Amanda L Fyles' 195 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site